Results 101 to 110 of about 56,351 (295)

Cannabinoids and Pain

Pain Research and Management, 2001
Cannabinoids have been used to treat pain for many centuries. However, only during the past several decades have rigorous scientific methods been applied to understand the mechanisms of cannabinoid action.
J Michael Walker, Nicole M Strangman, Susan M Huang   +2 more
doaj   +1 more source

Trends in toxicological findings and drug seizures of MDMA in New Zealand from 2010 to 2022

Journal of Forensic Sciences, EarlyView.
Abstract 3,4‐Methylenedioxymethamphetamine (MDMA) or “ecstasy,” is a commonly used drug worldwide, including in New Zealand, where 4.8% of the population aged 15 years or over reported using it in a 2023/2024 survey. This study provides additional insights on MDMA prevalence data in New Zealand by reporting toxicology data from Coronial and driving ...
Thomas J. Sheehan, Hilary J. Hamnett, Sarah G. G. Russell, Diana Kappatos, Helen Poulsen   +4 more
wiley   +1 more source

Targeting the LPI/GPR55 Axis in MAFLD and MASH: Novel Insights, Therapeutic Strategies and Future Directions. [PDF]

Liver Int
ABSTRACT Metabolic dysfunction‐associated fatty liver disease (MAFLD), recently redefined from non‐alcoholic fatty liver disease (NAFLD), highlights the central role of metabolic dysfunction in its pathophysiology. The L‐α‐lysophosphatidylinositol/G protein‐coupled receptor 55 (LPI/GPR55) axis, an element of the endocannabinoidome, has emerged as a key
Lian J, Lareu RR, Patil M, Falasca M.
europepmc   +2 more sources

Endocannabinoid system and anticancer properties of cannabinoids [PDF]

, 2016
Cannabinoids impact human body by binding to cannabinoids receptors (CB1 and CB2). The two main phytocannabinoids are Δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD).
Nowak, Agnieszka, Słomski, Ryszard, Zeyland, Joanna, Śledziński, Paweł   +3 more
core   +2 more sources

Pharmacological and Mechanistic Interventions for Cognitive Impairment Associated With Schizophrenia: A Review of Registered Clinical Trials

Acta Psychiatrica Scandinavica, EarlyView.
ABSTRACT Background Schizophrenia is characterized by positive, negative, and cognitive symptoms. Current pharmacological treatments often fail to address cognitive deficits. In this review of clinical trials, we aim to identify studies that explore neurobiological (non‐psychological) strategies to address Cognitive Impairment Associated with ...
Bahareh Peyrovian, Lena Palaniyappan, Theodore T. Kolivakis, Howard C. Margolese   +3 more
wiley   +1 more source

Amyloid proteotoxicity initiates an inflammatory response blocked by cannabinoids. [PDF]

, 2016
The beta amyloid (Aβ) and other aggregating proteins in the brain increase with age and are frequently found within neurons. The mechanistic relationship between intracellular amyloid, aging and neurodegeneration is not, however, well understood.
Currais, Antonio, Daugherty, Daniel, M Armando, Aaron, Maher, Pam, Quehenberger, Oswald, Schubert, David   +5 more
core   +2 more sources

Detecting cannabis use reduction through biochemical verification of urinary cannabinoids: An aggregated analysis of cannabis use disorder treatment trials examining average reductions and individual cut‐points

Addiction, EarlyView.
Abstract Background and aims Currently, there is no data‐driven cannabis reduction metric using biochemical verification, which represents a significant gap in cannabis harm reduction research, treatment and policy. Using aggregated data from 7 cannabis use disorder treatment trials, the aims of this analysis were to 1) determine if decreases in self ...
Erin A. McClure, Brian Neelon, Rachel L. Tomko, Ashley Dowd, Kevin M. Gray, Aimee L. McRae‐Clark, Nathaniel Baker   +6 more
wiley   +1 more source

Interaction between Cannabinoid System and Toll-Like Receptors Controls Inflammation [PDF]

, 2016
Since the discovery of the endocannabinoid system consisting of cannabinoid receptors, endogenous ligands, and biosynthetic and metabolizing enzymes, interest has been renewed in investigating the promise of cannabinoids as therapeutic agents.
McCoy, Kathleen L.
core   +4 more sources

Endocannabinoid system gene expression in mesocorticolimbic brain regions of individuals with alcohol use disorder: A descriptive study

Addiction, EarlyView.
Abstract Aims To describe differences in the expression of genes encoding cannabinoid receptors (CNR1, CNR2), the associated receptor GRP55 and the enzymes fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MGLL) between individuals with alcohol use disorder (AUD) and controls in key mesocorticolimbic brain regions.
María Salud García‐Gutiérrez, Abraham Bailén Torregrosa, Francisco Navarrete, Auxiliadora Aracil‐Fernández, Gabriel Rubio, Jorge Manzanares   +5 more
wiley   +1 more source

Expression of cannabinoid receptors in human osteoarthritic cartilage: implications for future therapies [PDF]

, 2016
Introduction: Cannabinoids have shown to reduce joint damage in animal models of arthritis and reduce matrix metalloproteinase expression in primary human steoarthritic (OA) chondrocytes. The actions of cannabinoids are mediated by a number of receptors,
Bunning, Rowena A.D., Crawford, Aileen, Dunn, Sara L., Le Maitre, Christine L., Wilkinson, Jeremy Mark   +4 more
core   +1 more source